CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06484920
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:27.573410+00:00
Published At: 2026-02-10T00:00:00+00:00
Record Updated At: 2026-02-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma", "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "B-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-10"
protocolSection.identificationModule.nctId: "NCT06484920"
protocolSection.identificationModule.officialTitle: "A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.